Contributions
Abstract: PB2126
Type: Publication Only
Background
Multiple myeloma (MM), the second most common hematological cancer, remains incurable. Its incidence is rising due to population ageing. Despite the impact of the disease and its treatment, not much is known about health-related quality of life (QoL) of patients with MM.
Aims
This study aimed to (1) Determine symptom prevalence in patients with MM on disease-modifying treatment, and identify the range and nature of these symptoms within the dimensions of physical, psychological, social well-being. (2) Measure the QoL of patients. (3) Compare the above-mentioned parameters to the general population.
Methods
Adults with multiple myeloma attending the hematology day unit in hematology department from November 2016 to January 2017 were eligible for inclusion in a cross-sectional. Consenting patients completed 2 validated questionnaires, the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) supplemented by the myeloma-specific module (EORTC QLQ-MY20) .
Results
Forty-seven patients were included for analysis: 51, 1% were male and 48,9% were female. Mean age was 64,7 years (range 42-82, standard deviation 11.50). The QoL scores were significantly lower than the general population (54,7 vs 71,2). The most commonly reported physical symptoms were pain (72%), fatigue (70%) and insomnia (66%). About 61 % of the patients were burdened by financial worries. On multivariate analysis, a good performans status (PS≤1) and a response of the disease to therapy (at least a partial response) were associated with high scores of QoL (P=0,01, P=0,03 respectively).
Conclusion
Patients with MM have a lower QoL than the general population and are symptomatic across physical, psychological and financial domains. They represent a polysymptomatic patient cohort with a complexity of need that merits a holistic multidisciplinary approach, and consideration of specialist symptomatic or palliative care review.
Session topic: 35. Quality of life, palliative care, ethics and health economics
Keyword(s): Quality of Life, Multiple Myeloma
Abstract: PB2126
Type: Publication Only
Background
Multiple myeloma (MM), the second most common hematological cancer, remains incurable. Its incidence is rising due to population ageing. Despite the impact of the disease and its treatment, not much is known about health-related quality of life (QoL) of patients with MM.
Aims
This study aimed to (1) Determine symptom prevalence in patients with MM on disease-modifying treatment, and identify the range and nature of these symptoms within the dimensions of physical, psychological, social well-being. (2) Measure the QoL of patients. (3) Compare the above-mentioned parameters to the general population.
Methods
Adults with multiple myeloma attending the hematology day unit in hematology department from November 2016 to January 2017 were eligible for inclusion in a cross-sectional. Consenting patients completed 2 validated questionnaires, the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) supplemented by the myeloma-specific module (EORTC QLQ-MY20) .
Results
Forty-seven patients were included for analysis: 51, 1% were male and 48,9% were female. Mean age was 64,7 years (range 42-82, standard deviation 11.50). The QoL scores were significantly lower than the general population (54,7 vs 71,2). The most commonly reported physical symptoms were pain (72%), fatigue (70%) and insomnia (66%). About 61 % of the patients were burdened by financial worries. On multivariate analysis, a good performans status (PS≤1) and a response of the disease to therapy (at least a partial response) were associated with high scores of QoL (P=0,01, P=0,03 respectively).
Conclusion
Patients with MM have a lower QoL than the general population and are symptomatic across physical, psychological and financial domains. They represent a polysymptomatic patient cohort with a complexity of need that merits a holistic multidisciplinary approach, and consideration of specialist symptomatic or palliative care review.
Session topic: 35. Quality of life, palliative care, ethics and health economics
Keyword(s): Quality of Life, Multiple Myeloma